For patients facing refractory or complex cancers who have exhausted standard treatment pathways, advanced cellular immunotherapy offers a genuine alternative. Universal Medical Travel partners with Bioocus Medical Group — spanning Tianjin Perennial Hospital and the Tianjin Cancer Hospital Airport Campus — to connect international patients with fourth-generation CAR-T cell therapy, TIL and NK cell treatments, and broad-spectrum cancer vaccines, delivered in modern international-standard wards.
This page focuses on Bioocus’s cellular immunotherapy programs. For full facility details, accreditation, and location information, see our complete Bioocus Medical Group profile.
Whether you’re exploring preventative options after surgery or investigating advanced cellular therapy for an aggressive or treatment-resistant cancer, our team coordinates every step of your medical case review and travel.
Therapeutic Modalities
Preventative & Recurrence Track
Peptide-Based Cancer Vaccine Research (including TP53-targeted approaches) — Bioocus researches peptide-based vaccines intended to activate T-cell and NK-cell responses, explored as a preventative or post-surgical recurrence-reduction measure. This is a research-stage area; ask your care coordinator for current availability and published outcome data before relying on it for treatment planning.
Advanced Cellular Therapies
Fourth-generation IL-15-expressing CAR-T, TIL, and NK cell therapies targeting hematologic malignancies (B-ALL, Multiple Myeloma, AML) and aggressive solid tumors, including Neuroblastoma, Brain Glioma, Advanced Gastric Cancer (CLDN18.2-targeted), and Hepatocellular Carcinoma.
Clinical Infrastructure
- A dedicated cellular therapy research laboratory
- A GMP-certified cell manufacturing facility
- International-standard wards with 24/7 ICU protection
- English-speaking clinical staff
- Dedicated international patient care coordinators
Documented Outcomes
The following response rates are reported by Bioocus Medical Group from their own treated patient cohorts. Individual outcomes vary by diagnosis, disease stage, and treatment history — a full case review is required before any outcome can be estimated for your specific condition.
| Treatment Category | Reported Outcome |
|---|---|
| Hematologic malignancies (CAR-T) | 90% complete response (CR) rate; 95%+ overall response rate (ORR) — reported by Bioocus, bioocus.com |
| Aggressive solid tumors | Documented disease control in a substantial share of treated cases |
Concierge Care Steps
- Remote preliminary multidisciplinary team (MDT) assessment of your medical records
- Visa processing assistance
- 24/7 airport pickup on arrival
- Long-term telemedicine follow-up once you return home
How We Help You
Step 1: Submit your patient form and medical records
Step 2: Receive a preliminary MDT case review
Step 3: Confirm your personalized treatment plan
Step 4: Travel to China for treatment
Step 5: Receive care with full concierge support
Step 6: Return home with telemedicine follow-up
Flexible Budget Options
Advanced cellular therapy pricing varies by diagnosis and treatment plan. If your budget is a concern, our coordinators can also connect you with more cost-flexible cancer care options — see our guide to cancer treatment in China or the most affordable countries for cancer treatment to compare regional options before you begin your medical tourism journey.
Start Your Medical Journey
Get started today and let our team handle everything for you.
📄 Patient Form: https://universalmedicaltravel.com/patient-information-form/
🎁 Use Discount Code: UMT5%
💬 WhatsApp Support Available 24/7
Get Exclusive Discount
Please submit the patient form to qualify for the Discount Code or any promotions that are available. If you contact the clinic directly before submitting the form, you will receive the standard prices.
Submit your patient form & begin your medical tourism journey today!